Show
Sort by
-
Does a patient's self-reported health-related quality of life predict survival beyond key biomedical data in advanced colorectal cancer?
-
Capecitabine, Oxaliplatin, radiotherapy and excision (CORE) in patients with MIR-defined locally advanced rectal adenocarcinoma: results of an international multicenter phase II study
(2006) -
The value of patient-reported symptoms as prognostic factors for survival in advanced colorectal cancer
-
An international phase II study of Capecitabine, Oxaliplatin, Radiotherapy and Excision (CORE) in patients with MRI-defined locally advanced rectal adenocarcinoma. Interim results.
-
Report on the Belgian consensus meeting on Colorectal cancer screening
-
Optimisation of irinotecan dose in the treatment of patients with metastatic colorectal cancer after 5-FU failure: results from a multinational, randomised phase II study
-
Phase II study of irinotecan + 5FU/FA for patients with previously treated advanced gastric cancer
-
Raltitrexed plus Gemcitabine (TOMGEM) in advanced pancreatic cancer - Results of a Belgian Multicentre Phase II Study
-
Pharmacodynamic studies of tumor biopsy specimens from patients with advanced gastric carcinoma undergoing treatment with genfinitib (ZD1839)
-
Raltitrexed/gemcitabine in patients with advanced biliary tract adenocarcinoma: a phase II study